Loading...
XNAS
PACB
Market cap500mUSD
Jul 09, Last price  
1.61USD
1D
7.33%
1Q
20.15%
Jan 2017
-57.63%
IPO
-90.51%
Name

Pacific Biosciences of California Inc

Chart & Performance

D1W1MN
XNAS:PACB chart
P/E
P/S
3.13
EPS
Div Yield, %
Shrs. gr., 5y
11.38%
Rev. gr., 5y
15.19%
Revenues
160m
+3.89%
2,163,000901,000135,0001,674,00033,863,00025,983,00028,181,00060,594,00092,782,00090,714,00093,468,00078,626,00090,891,00078,893,000130,513,000128,304,000200,521,000154,014,000160,005,000
Net income
-546m
L+76.34%
-21,518,000-43,754,000-87,703,000-140,166,000-109,388,000-94,465,000-79,293,000-66,160,000-31,696,000-74,375,000-92,189,000-102,562,000-84,134,00029,403,000-181,223,000-314,248,000-306,735,000-309,851,000-546,376,000
CFO
-111m
L-46.03%
-16,732,000-38,303,000-74,838,000-121,996,000-102,974,000-76,822,000-29,833,000-51,468,000-47,889,000-67,929,000-67,518,000-66,430,000-78,312,00019,503,000-111,180,000-263,211,000-266,548,000-206,058,000-111,209,000
Earnings
Aug 03, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
IPO date
Oct 27, 2010
Employees
769
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT